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ADVERSE DRUG REACTIONS 
 
In its simple definition an ADR is any undesirable effect of drug beyond its 
anticipated therapeutics occurring during clinical use. The WHO defines an ADR as ''any 
response to a drug which is noxious and unintended, and which occurs at doses normally 
used in man for prophylaxis diagnosis or therapy of disease, or for the modification of 
physiologic function''. Thus this definition excludes overdose [either accidental or 
intentional], drug abuse, and treatment failure and drug administration errors.
[1]
 
 
Adverse reactions are recognized hazards of drug therapy. ADR's are important 
causes of mortality and morbidity in both hospitalized and ambulatory patients. In many 
countries ADR's rank among the top ten leading causes of mortality. So there is a need to 
study ADR's seriously to create awareness about ADR among patients to motivate health 
care professionals in the hospital to report ADR's to minimize the risks. Early detection, 
evaluation and monitoring of ADR are essential to reduce harm to patients and thus improve 
public health 
[2]
. 
 
The safety of drug prescribing has become a highly visible topic in adult medicine, 
due in part to research suggesting that these are important ADRs caused by commonly used 
medications. Much less attention has been focused on neonates, infants, children and 
adolescents. To date, almost all investigations of ADRs have been performed in adult 
populations. There is recent evidence that potential ADRs may be more common in 
paediatirics, suggesting that the epidemiologic characteristic of medication errors may be 
different between children and adults.
[7]
 
 
The use of medicines in children is an area of increasing interest. Infancy and 
childhood is a period of rapid growth and development. The varies organs, body system and 
enzymes that handle drugs develop at deferent rates and present a challenge to paediatrician, 
since drug dosage, formulations, response to drugs and adverse drug reaction vary through 
out childhood. Clinicians need to ensure not only that toxicity is kept to a minimum but also 
that children are not denied the use of appropriate medicines. Drug use in children may be 
accompanied by problems not seen in adults, or cause adverse drug reactions that are more 
frequent than in adults.
 [8]
 
INTRODUCTION  
Ultra college of pharmacy, Madurai  Page 2 
 
An example of this is metoclopramide, which causes dystonia in teenagers and 
Parkinsonism in the elderly. 
 
Paediatric patient constitute a vulnerable group with regard to rational drug 
prescribing. Since many new drugs are released in to the market without the benefit of even 
limited experience in this age group. This deficiency causes paediatricians to often prescribe 
children drugs in an “off – label” manner, thereby increasing the risk of drug toxicity[7]. 
 
Drug toxicity is a major limitation in providing healthcare to patients at a global 
level. It affects the patient's recovery as well the economy of healthcare. With the increase 
in production of various pharmaceutical products, newer drugs are being introduced every 
year. Hence, the need for an active surveillance system to remove the harmful drugs that 
have entered the market was well realized by WHO. This has been the basis for starting the 
international drug monitoring programme by WHO. 
[3]
 
 
In 1960 food and drug administration [FDA] began to collect reports of ADR and 
sponsor hospital drug monitoring and in 1964 yellow card scheme was started in UK. 
WHO's programme for international drug monitoring was started in 1968. Initially a pilot 
project in 10countries with established national reporting systems for ADR's. The network 
has since expanded significantly as more countries world-wide developed national 
pharmacovigilance centres for recording of ADR's. Currently 86 countries participate in the 
program which is coordinated by WHO together with its collaborating centre in 
Uppsala,Sweden.
[4]
 
 
ADRs have a considerable negative impact on both health and healthcare costs. 
ADR monitoring and reporting activity is in its infancy in India because   significant drug 
use problems like availability of prescription drugs over the counter, the simultaneous 
practice of different systems of health care, lack of awareness of rational drug use in 
the community including widespread antibiotic resistance and the occurrence of drug 
induced illness, non- availability of prescribing  guidelines,  the number of drugs  
prescribed  are high,  the ever increasing number of new drugs in the market, the lack of 
formal system for monitoring adverse drug reactions, and the lack of restrictions on the use 
of a large variety of drugs in health care delivery in the private sector may result in a 
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higher incidence of adverse drug reactions.
[5,6]
 
 
Monitoring of adverse drug reactions started in India about two decade ago (1982). 
Under the Chairmanship of the Drug Controller of India, five centres were established with 
the idea of starting a monitoring programme nationwide. Its nodal centre (National 
Pharmacovigilance Centre) is  located  in  the Department of Pharmacology, All India 
Institute of Medical Sciences, and New Delhi. It is affiliated to WHO collaborating centre 
for ADR Monitoring, Uppsala, Sweden. The others are located in PGI (Chandigarh), 
JIPMER (Pondicheri), KGMC (Lucknow) and Seth GS Medical College (Mumbai)-special 
centre. It consists of three phases: the first one being monitoring of reactions in the 
institutes, second one in governmental bodies like Central Governmental Health Scheme 
(CGHS), and the third phase proposed to include general practitioners. 
 
Most of the adverse drug reaction monitoring programs rely on physician initiated 
reporting (voluntary reporting) and have been partially successful. Underreporting has 
been the biggest challenge in the voluntary reporting method and several reasons like 
increase in workload, perception that reporting will not result in any improvement and lack 
of knowledge that an adverse event has occurred and fear of exposing oneself to litigation. 
To overcome the problems  in  the  voluntary  reporting  of  adverse  drug  reactions,  
prompted  spontaneous reporting is followed wherein physicians are prompted by medical 
residents, pharmacists or nurses to report any adverse drug reactions. This method of 
prompting the physicians every day is reported to increase the reporting and reducing the 
morbidity and mortality. Today’s well  trained  pharmacists  possesses  a  sound  knowledge  
of  the  adverse  effects  of  drugs including  their  predictability,  reversibility,  frequency,  
severity,  predisposing  factors  and relationship to dosage and  their treatment and 
prevention. 
 
Less information is available regarding the epidemiology and prevention of 
medication errors and ADRs in paediatiric in patient settings. Children pose unique 
challenge to the system for ordering, dispensing, administering and monitoring medication. 
Since weight – based dosing is needed for virtually all drugs in paediatrics, ordering 
medication typically involves more calculations than for adults. Dispensing drug in 
paediatrics is also error – prone because pharmacists often must dilute stock solution. The 
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cardiovascular system of a premature baby maybe unable to cope with even a small error in 
the dosage of an inotropic agent
[10]
. 
 
Errors in calculating drug doses have long been recognized as an iatrogenic cause of 
morbidity and mortality. Error by a factor of 10 (the administration of a dose 10 times or 
1/10 as high as appropriate) are of particular concern. There is a greater chance that an 
infant or a young child will receive such a dose of medication than that an adult will, 
because even a dose 10 times as high as the appropriate paediatric dose may represent an 
unsuspiciously small volume of stock solution
[11]
. 
 
Also to draw attention to an insidious form of medication error that can occur at the 
pharmacy dispensing stage, which to the best of knowledge has hitherto gone unreported: 
the provision of paper packets containing incorrect dosages of powder obtained from 
crushed tablets
[16]
. 
 
Many drugs used to treat children in hospital are either not licensed for used in 
children or are prescribed outside the terms of their product license. Use of off label drugs 
include diazepam rectal solution in children under 1 year (not licensed for age group), 
amiloride tablets in any children(formulation),or rectal injection of lorazepam for a child 
with an acute seizure(route). An example of unlicensed use is the preparation of a 
suspension from a tablet by the hospital pharmacy.  
 
Categories of unlicensed use were modification of licensed drugs (such as crushing 
tablets to prepare a suspension), drugs that are licensed but the formulation is manufactured 
under a special license (such as liquid preparation of a drug that is licensed only in tablet 
form). New drugs available under a special manufacturing licensed (such as caffeine 
injection for apnoea of prematurity). Use of chemicals as drugs when no pharmaceutical 
grade preparation is available and imported drugs (drugs imported from a country where 
they are licensed). Off label use included use of a drug in situations not covered by the 
product license or summery of product characteristics that is, at a different dose or 
frequency in different clinical indication in different age groups, administration by an 
alternative route, or in a formulation not approved for use in children. 
 
Although important advances have been made in paediatric clinical pharmacology, 
there is still a dearth of information on many aspects of adverse drugs reactions in children. 
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The risk of ADRs is increased in the neonates, especially when premature because of the 
enzymes involved in drug metabolism and elimination are poorly developed
[8]
. 
 
Adequate controlled clinical trails in children are lacking, mainly because of issues 
of cost and responsibility, and to regulations that  frequently  act  as  major  obstacles.  
Moreover, until recently, the few clinical trails that had been performed involving children 
focused on the efficacy of drugs and rarely monitored their safety. If improvements in the 
safety of medical care for children are to take place, additional research quantifying the 
incidence of more generally occurring complication and describing epidemiology of those 
iatrogenic complication is required. 
 
DEFINITION 
 
Some of the most commonly cited definitions are: 
 The WHO has defined as ADR an “any response to a drug which is noxious 
and unintended,  and  which  occurs  at  doses  normally  used  in  man  for  
prophylaxis, diagnosis or therapy of a disease or for the modification of 
physiological functions.”  
 The Joint Commission on the Accreditation of Healthcare Organizations 
(JCAHO) defines an adverse drug reaction (ADR) as an undesired effect of a 
medication that either increases toxicity, decreases desired therapeutic effect, or 
both
[9].
 
 Food and Drug Administration (FDA), for reporting purposes, categorizes a serious 
adverse event as one in which the patient outcome is death, life threatening (real 
risk of dying) hospitalization (initial or prolonged) disability (significant,  
persistent or permanent), congenital anomaly or required intervention to prevent 
permanent impairment or damage. Wills & Brown have given the definition for an 
ADR “an unintended, harmful or potentially harmful reaction which results from 
the administration of a single medicine at clinical doses. 
 *American Society of Hospital Pharmacists (ASHP) defines a significant ADR as 
any unexpected, unintended, undesired, or excessive response to a drug that: 
Requires discontinuing the drug (therapeutic or diagnostic)Requires changing the 
drug therapy, Requires  modifying the  dose (except  for minor dosage  
adjustments),  Necessitates admission to a hospital, Prolongs stay in a health care 
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facility,  Necessitates supportive treatment,  Significantly   complicates   diagnosis,   
Negatively affects prognosis, or results in temporary or permanent harm, 
disability, or death. Consistent with this definition, an allergic reaction (an 
immunologic hypersensitivity, occurring as  the  result  of  unusual  sensitivity  to  
a  drug)  and  an  idiosyncratic  reaction  (an abnormal susceptibility to a drug that 
is peculiar to the individual) are also considered as ADRs.
[9]
 
 
EPIDEMOLOGY: 
 
They are a major clinical problem accounting for 2-6% of all hospital admissions. It 
causes significant financial burden on national health budget. ADRs are important causes of 
mortality and morbidity in both hospitalised and ambulatory patients. Many ADRs are due 
to irrational prescribing under diagnosis .More than four drugs in one prescription may lead 
to ADRs. 8-10% of hospital admissions may develop ADRs. Over to million serious ADRs 
reported yearly, one lakh deaths yearly caused due to ADRs. It adversely affects the 
patients quality of life. It causes patients to lose confidence in their doctors. It 
increases costs of patients care and may mimic disease resulting in unnecessary 
investigations and delay in treatment. 
[9,3,1]
 
 
CLASSIFICATIONS OF ADRs 
 
There are many ways of classifying ADRs, Some of the generally used 
classifications are mentioned below. 
 
1. Rawlins &Thompson Classification: 
 
Type-A (Augmented): Commonest (up to 70%) – Dose dependent, severity increases with 
dose, preventable in most part by slow introduction of low dosages. Type A is predictable 
by the pharmacological mechanisms. 
Eg: Hypotension by beta-blockers 
 
Type-B (Bizarre):   Rare, idiosyncratic, genetically determined, unpredictable, 
mechanisms are unknown, serious, can be fatal and unrelated to the dose. 
Eg: Hepatitis caused by halothane 
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Type-C (Continuous drug use):   It occurs as a result of continuous drug use. It may 
be irreversible, unexpected and unpredictable. 
Eg:  Tardive dyskinesias by antipsychotics 
 
Type-D (Delayed): Delayed occurrence of ADRs, even after the cessation of treatment. Eg: 
Opthalmopathy after chloroquine. 
 
Type-E (End of dose): Withdrawal reactions. It occurs typically with the depressant drugs. 
Eg: Hypertension and restlessness in opiate abstainer. 
 
Type-F (Failure of therapy): Results from the ineffective treatment. Eg: Accelerated 
hypertension because of inefficient control. 
 
2. Wills and Brown Classification: 
 
Type  A  (Augmented):  These  include  the  common,  pharmacologically  predictable,  
dose related reactions, which improve when the medicine is withdrawn. 
 
Type B (Bugs):   These are pharmacologically predictable and they also improve when 
the medicine is withdrawn but they involve interaction with a microorganism. 
Eg: Sugar containing medicine promoting dental caries. 
 
Type C (Chemical): These involve irritant actions related to drug concentration. Eg: Contact 
dermatitis. 
 
Type D (Delivery): These reactions are caused by the method of administration used or the 
nature of formulation. They improve when the medicine is withdrawn or the method of 
delivery changed. 
Eg: Inflammation or fibrosis around implants. 
 
Type E (Exit): These reactions are pharmacologically predictable but they begin only when 
the medicine is withdrawn or the dose is reduced. They improve when the medicine is 
reintroduced. 
Eg: Well established withdrawal reactions with opioids, benzodiazepines. 
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Type F (Familial): These reactions occur only in susceptible individuals with 
genetically determined, inherited, metabolic disorders.  They improve when the medicine is 
withdrawn. 
Eg: Patients suffering from G6PD deficiency may experience hemolysis when exposed to 
quinine. 
Type G (Genotoxicity): A number of drugs can produce irreversible genetic damage in 
humans. Notably some are potentially carcinogenic or genotoxic. Some teratogenic agents 
damage genetic material with in the foetus. 
Eg: Metronidazole 
 
Type H (Hypersensitivity): These reactions require activation of immune system.   
They improve when the medicine is withdrawn. 
Eg: Anaphylaxis,   Allergic skin rashes 
 
Type U (Unclassified): Some reactions are produced by mechanisms, which are still 
not understood, and these must remain unclassified until more is known about them. 
Eg: Metronidazole induced taste disturbance, Muscular adverse effects of simvastatin
[10].
 
 
3. Immunologic and Nonimmunologic Drug Reactions: 
 
Drug reactions can be classified into immunologic and nonimmunologic 
etiologies. The majority (75 to 80 percent) of ADRs are caused by predictable, 
nonimmunologic effects. The remaining 20 to 25 percent of adverse drug events are 
caused by unpredictable effects that may or may not be immune mediated. 
 
Immunologic: 
 
Type 
 
Type I reaction (IgE-mediated) Eg Anaphylaxis from b-lactam Antibiotic 
Type II reaction (cytotoxic) - Hemolytic anaemia from Penicillin 
Type III reaction (immune complex) - Serum sickness from anti- thymocyte globulin. 
Type IV reaction (delayed, cell-mediated) - Contact dermatitis from topical   antihistamine 
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Nonimmunologic: Predictable 
Pharmacologic side effect - Dry mouth from antihistamines 
Secondary pharmacologic side effect - Thrush while taking antibiotics 
Drug toxicity - Hepatotoxicity from methotrexate 
Drug-drug interactions - Seizure from Theophylline while taking erythromycin 
Drug overdose - Seizure from excessive lidocaine. 
 
Unpredictable 
 
Pseudo allergic - Anaphylactoid reaction after radiocontrast media 
Idiosyncratic - Hemolytic anemia in a patient with G6PD deficiency after primaquine therapy 
Intolerance - Tinnitus after a single, small dose of   Aspirin 
 
4.   Gell and Coombs Classification of Drug Hypersensitivity Reactions: 
 
The  Gell  and  Coombs  classification  system  describes  the  predominant  
immune mechanisms that lead to clinical symptoms of drug hypersensitivity. 
 
Type I (IgE-mediated):  The timing of reactions is minutes to hours after drug exposure. 
Mechanism - Drug-IgE complex binding to mast cells with release of Histamine, mediators. 
Clinical manifestations  -  Utricaria,  angioedema,  bronchospasm,  inflammatory  pruritus, 
vomiting, diarrhoea, anaphylaxis. 
 
Type II (cytotoxic): The timing of reactions is variable. 
Mechanism - Specific IgG or IgM antibodies directed at drug-hapten coated cells. Clinical 
manifestations - Hemolytic anaemia, neutropenia, thrombocytopenia. Type III (immune 
complex): Reaction occurs 1 to 3 weeks after drug exposure. 
Mechanism - Tissue deposition of drug-antibody complexes with complement activation 
and inflammation. 
Clinical manifestations - Serum sickness, fever, rash, arthralgia, urticaria, Lymphadenopathy, 
glomerulonephritis, and vasculitis. 
 
Type  IV  (delayed,  cell-mediated):  Reaction  occurs  2  to  7  days  after  cutaneous  
drug exposure. 
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Mechanism - MHC presentation of drug molecules to T cells with cytokine and 
Inflammatory mediators release. 
Clinical manifestations - Allergic contact dermatitis, Maculopapular drug rash.
 
 
PREDISPOSING FACTORS 
 
Three major determinants to drug response; the drug itself, the patient and the 
extrinsic factors.  Factors related to these determinants serve as criteria for selective clinical 
monitoring of patients as they often predispose the patient to adverse drug reactions. 
 
1. Drug related factors 
 
a. Dose: Ingestion of excessive amounts of a drug will cause a more intense 
pharmacological response and a greater likelihood of adverse effects. Eg: Patients 
with herpes genitalis will overuse acyclovir which apart from adverse effects may 
even lead to drug resistance. 
 
b. Formulation: Particle size, tablet disintegration time and dissolution rate, presence 
of excipients  in  dosage  form  and  degree  of  purity  influence  drug  absorption  
and  thus  the potential for adverse effects.   The macro crystals of Nitrofurantoin 
are associated with less gastrointestinal adverse effects than microcrystalline 
formulation. 
 
c. Physicochemical properties: Physiocochemical properties including pH, degree of 
ionization, lipid solubility, protein binding and extent of first pass metabolism can 
alter the bioavailability of a drug.  A highly lipid soluble beta blocker propranolol 
appears to have a greater incidence of central nervous system effects relative to less 
lipid soluble compound like nadolol, atenolol or timolol. 
 
d. Rate and route of administration: The route of administration of a drug will 
influence its bioavailability. The I.V route provides for complete bioavailability 
while the I.M and rectal routes have slower and more erratic absorption patterns.  
The bioavailability from oral route will depend on such factors as stability of a drug 
in GI fluids, extent of first pass metabolism and other physicochemical properties.   
There is the possibility of increased cardio toxicity with a single IV bolus injection 
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of doxorubicin as compared to continuous infusion, and there exists  an  increased  
incidence  of  nephrotoxicity with  faster  infusion  rates  of  cisplatin  as compared 
to slower rates. 
 
2. Patient related factors a) Age 
 
i. Geriatrics:  Patients  above 60  years of age  are more likely to  develop  adverse 
drug reactions and may even need hospitalization due to adverse drug reactions.  
Reasons may be due to polypharmacy, poor compliance, concurrent medical illness, 
and alterations in pharmacokinetic  and  pharmacodynamic  parameters.  For  
example,  the  elderly  have  an increased incidence of digoxin toxicity because of 
impaired renal function, cardiovascular disease and electrolyte imbalance. 
 
ii. Paediatrics: Incompletely developed intrinsic defence mechanisms predispose 
infants and neonates to infections and risks such as kernicterus or haemolytic anemia 
with sulfonamides and hearing loss with amino glycosides.   Developmental bone 
growth can be retarded with the use of tetracyclines and corticosteroids in children 
younger than eight years of age. Percutaneous absorption of drugs is significantly 
enhanced in infants and children. Topical use of aminoglycoside-polymyxin sprays 
in young children has lead to permanent hearing  loss  and  hexachlorophene  sprays  
in  neonates  has  caused  neurotoxic  related  to increased absorption. 
 
b) Gender: A higher incidence and more hospital admissions due to adverse drug reactions 
have been documented for women compared to men.   Possible reasons for the 
increased adverse drug reactions include the observations that women take more drugs 
than men, differences in perceptions of ADRs, pharmacology of ADRs, differences in 
kinetics such as volume of distribution leading to gender associated differences in drug 
exposure, polypharmacy and hormonal differences between men and women. 
Chloramphenicol induced aplastic anemia and phenyl butazone induced agranulocytosis 
is twice and thrice as common, respectively in women patients. 
 
c) Pregnancy: The use of drugs presents special problems during pregnancy leading from 
extension of their pharmacological effects on the fetus and neonate to extensive 
teratogenicity. Drugs like phenytoin, haloperidol, androgens, diethylstilbosterol, and 
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anticancer drugs like cytarabine and methotrexate have been associated with marked 
tertogenic effects. 
 
d) Concurrent diseases 
 
i. Hepatic disease:  Liver failure can alter the action of any drug that depends on the 
normal function of the liver for its metabolism. Impaired hepatic metabolism can 
precipitate hepaticcoma with barbiturates or morphine, mental confusion and 
convulsions with cimetidine and seizures with lidocaine or theophylline. 
 
ii. Renal disease: Renal failure increases the incidence of adverse drug reactions 
especially for drugs, which depend on the kidney for their elimination.   Delayed 
renal excretion is responsible for enhanced toxicity of drugs like allopurinol, amino 
glycosides, digoxin, etc. 
 
e) Genetics: Hereditary factors have been shown to predispose individuals to increased 
toxicity to drugs such as succinylcholine, isoniazid, monoamine oxidase inhibitors, 
hydralazine and procainamide. Patients with deficiency of Glucose-6-phosphate 
dehydrogenase (G6PD) enzyme may develop hemolytic anemia on exposure to oxidant 
drugs such as dapsone, sulfapyridine, primaquine and nitrofurantoin. 
 
f) Nutrition: The nutritional status of a patient is another factor predisposing to adverse 
drug reactions.   Monoamine oxidase inhibitors with foods rich in tyramine e.g. aged 
cheese and aged wines to cause hypertensive crisis with intracranial bleeding.   
Another drug-nutrient interaction is related to the sodium, potassium and alcohol 
content of drugs.  Salt substitute containing potassium can cause hyperkalemia in the 
presence of potassium sparing diuretics, e.g. spironolactone. 
 
3. Extrinsic factors 
 
Environmental temperature has been cited as a predisposing factor to adverse drug 
reactions.  Drug  with  significant  anticholinergic  activity e.g.,  atropine,  antipsychotics  
and tricyclic antidepressants have precipitated heat strokes in persons exposed to hot 
temperature and high humidity climates.  Diuretics such as thiazide may also cause 
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photosensitivity and even excessive loss of fluid and salt, which has negative implications 
for persons in hot environment. 
 
4. Multiple drug therapy 
 
Incidence of ADRs increase exponentially with the number of drugs prescribed 
and consumed indicating that the effects of multiple drugs are not always additive and 
safe. High prescribing rates are usually associated with the severity of disease and 
seriously ill patients are often predisposed to certain drug reactions.  Other factors like 
drug interactions may also be responsible for the symptoms attributed to adverse drug 
reactions.
[12,9] 
 
ADR IN PAEDIATRICS 
 
A wide range of drugs has been reported as being involved in ADR's in children. 
This include antibiotics NSAIDS, opiates, tuberculostatics, immunosuppressive agents, 
anticonvulsants etc. Incompletely developed intrinsic defense mechanisms predispose 
infants and neonates to infections and risks such as kernicterus or haemolytic anemia with 
sulphonamides and hearing loss with amino glycosides. Developmental bone growth can be 
retarded with the use of tetracyclines and corticosteroids in children younger than 8 years of 
age.  Percutaneous  absorption  of  drugs  is  significantly  enhanced  in  infants  and  
children. Topical use amino glycoside- polymyxin sprays in young children has lead to 
permanent hearing  loss  and  hexachlorophene  sprays  in  neonates  has  caused  neuro  
toxic  related  to increased absorption.
[12] 
 
ADR's has been reported to occur frequently in children but not as frequently as in 
adults. Infants and very young children are at high risk of developing adverse drug reactions 
than adults because their capacity to metabolize drugs is not fully developed. For 
example new born cannot metabolize and eliminate the antibiotic chloramphenicol, new 
born who are given  the  drug  may develop  grey baby syndrome,  a  serious  and  often  
fatal  reaction.  If tetracyclin another antibiotic is given to infants and young children during 
the period when their teeth are being formed [upto about age 8 years] it may permanently 
discolour tooth enamel. 
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There are few publications among   paediatric   patients, though ADR incidence is 
usually stated to be higher in paediatric population. ADR's may adversely effects patients 
quality of life. It increases costs of patient care and may mimic disease resulting 
unnecessary investigation and delay treatment. 
 
PROCEDURE FOR REPORTING ADVERSE DRUG REACTION 
1. WHAT TO REPORT 
Any undesirable adverse event suspected to be associated with use of drug; 
biological (including blood products), herbal drugs, cosmetics or medical devices should be 
reported. They should include; 
1. All ADRs as a result of prescription and non-prescription. 
2. All suspected adverse drug reactions regardless of whether or not the product was 
used in accordance with the product information provided by the company marketing 
the product. 
3. Unexpected reaction, regardless of their nature or severity, whether not consistent 
with product information or labelling. 
4. An observed increase in frequency of a given reaction. 
5. A serious reaction, whether expected or not. 
6. All  suspected  ADRs  associated  with  drug-drug,  drug-food  or  drug-food  
supplements interactions. 
7. ADRs in special field of interest such as drug abuse and drug use in pregnancy and 
during lactation. 
8. ADRs occurring from overdose or medication error. 
9. Unusual lack of efficacy or when suspected pharmaceutical defects are observe 
 
2. INFORMATIONS REQUIRED FOR AN ADR CASE REPORT 
 
The minimal standard information to be provided for proper assessment of the 
ADR case report are; 
1. Patient information 
2. Adverse reactions description (include laboratory results if available) 
3. Information related to the suspected drug(s) 
4. Information on management of the adverse reactions 
5. Information about the reporter 
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I. Patient information 
 
1. Patient identity: indicate initials or record number of the patient in hospital, 
medical institution, dispensary, clinic or pharmacy. 
2. Birth dates or age: indicate date, month and year 
3. Sex: Male or Female 
4. Weight: should be in Kilograms. 
 
II. Adverse reaction(s) 
 
1. Brief description of the ADR(s): Indicate the adverse(s) reaction by marking X in the 
appropriate box. Preferably describe briefly the nature of the adverse reaction being 
reported but as clearly as possible, including the body site and severity. 
2. Time/date of onset of the adverse reactions: State the time of onset or the occurrence 
of the adverse reaction in relation to the administration of the drug. Indicate the date of 
onset in the following order; day, month and year. 
3. Other relevant information: Patient medical history or laboratory data including dates 
if available, considered relevant to the case or the adverse reaction being reported 
should be entered. Mention appropriate laboratory tests done to the patient and results to 
confirm the adverse reaction. State this concisely but clearly. 
 
III. Suspected drug(s) 
 
1. Name of the suspected drug (s): trade name should preferably be used, if trade name 
not available, generic name may be used. Strength of the drug (s) should be stated 
2.   Dosage, frequency and route of administration should be clearly notified. For example; 
1. Dosage (specify dosage form; tablet, capsules, syrup, injection,cream, eye 
drops, etc.  including total amount of drugs). 
2. Frequency: specify unit first i.e. mg, ml, mg/kg and number of time given 
e.g. 4 times daily or q.i.d. 
3. Route of administration by which the drug was administered. 
4. Therapy date: the dates of beginning and termination of the administration 
of each drug should be stated, and preferably recorded as follows:- date, 
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month and year 
5. Batch number and expiry date: provide these information if available. 
6. Reason for use: state indication or condition for which the drug(s) was given 
for. 
7. Particular of concurrently drugs(or other treatment): state particulars of 
other drug (s) administered by the patient concurrently with the suspected 
drug, including drug administration for at least 1 month back with dosage, 
route of administration, duration of administration and indications. 
8. Provide relevant information on medical devices 
 
3. HOW TO RECOGNISE ADRs 
 
Since ADRs may act through the same physiological and pathological pathways as 
different diseases, they are difficult and some-times impossible to distinguish. However, the 
following steps-wise approach may be helpful in assessing possible drug-related ADRs. 
1. Ensure that the medicine ordered is the medicine received and actually taken by 
the patient at the dose advised; 
2. Verify that the onset of the suspected ADR was after the drug was taken, not 
before and discuss carefully the observation made by the patient; 
3. Determine the time interval between the beginning of drug treatment and the onset 
of the event. 
4. Evaluate the suspected ADR after discontinuing the drugs or reducing the dose 
and monitor the patient‟s status.  If appropriate restart the drug treatment and 
monitor recurrence of any adverse events. 
5. Analyse the alternative causes (other than the drug) that could on their own 
have caused the reaction; 
6. Use relevant up to date literature and personal experience as a health professional 
on drugs and their ADRs and verify if there are previous conclusive reports on this 
reaction. 
7. Report any suspected ADR to the person nominated for ADR reporting in the 
hospital or directly to the national ADR centre. 
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4. MANAGEMENT OF THE ADVERSE REACTION 
 
1. Confirmation of the ADRs: indicate what assisted in confirming the suspected 
adverse reactions. 
For example: 
a) Drug   reactions   confirmed   by   disappearance   of   the   reaction   after   
stopping administration of the drug or reducing the doses. 
b) Recovery on withdrawal of suspected drug(s) if no other drug is withdrawn 
and no therapy given. 
c) Recovery follows treatment of the reaction in addition to withdrawal of drug. 
2. Mention the criteria for regarding the reaction as serious. 
3. Mention any treatment given to the patient after experiencing the ADRs. 
4. Outcome: indicate the outcome of the adverse reaction by marking X in the 
appropriate box with dates in case of fatal outcome. 
 
5. REPORTER INFORMATION 
 
Details on reporter of an ADR: mention your particulars:-name, address of the health 
facility (hospital, institution, dispensary, clinic, company, pharmacy or maternity home). E- 
mail address (optional), signature, telephone number and date of reporting the reaction 
(indicate date, month and year). 
 
6. WHO SHOULD REPORT 
 
Reporters should bear in mind that any information related to the reporter and 
patient identities shall be kept confidential. The following should provide reports of any 
case of suspected ADRs when encountered to the patient as part of their professional 
responsibility:- 
1. All health care professionals   including specialists, doctors, dentists, pharmacists, 
nurses, assistant medical officers, clinical officers, pharmaceutical technicians, 
pharmaceutical  assistants, traditional medicine  practitioners and others health  
care providers. 
2. Manufacturers or Product registrants. 
3. All government hospitals, private hospitals, health centres, dispensaries private 
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clinics, private pharmacies and private nursing homes have obligation to report all 
ADR cases encountered or reported to them by the patients. 
 
7. WHEN TO REPORT 
 
Any suspected ADR should be reported as soon as possible. Delay in reporting will 
make reporting inaccurate and unreliable. If possible, report while the patient is still in the 
health facility this gives a chance to reporter to clear any ambiguity by re-questioning or 
examining the patient. 
 
8. BASIC PRINCIPLES OF EFFICIENT REPORTING 
 
1. Report the adverse reaction immediately after it occurs. 
2. If possible, take the decision to report whilst the patient is still with you, so that 
the details can be filled in at once on the reporting form. 
3. Think about any other factors which may contribute in causing the event such as 
other prescribed drugs, self-medication, herbal products, food, chemicals, ask the 
patient particularly about other medicines taken. 
4. If you get any supplementary data later, e.g. if the same patient develops the 
effect again or if something happens which increases your suspicion or seem to 
exclude the reaction, please send in a supplementary note immediately using ADRs 
reporting form with the patient identifiers. 
5. All reports must have the following four data elements  
i. An identifiable patient  
ii. A suspected adverse effect  
iii. A named suspected drug (s)  
iv. An identifiable reporter 
6. Always write legibly. 
[13,14]
 
 
9. METHODS OF MONITORING ADVERSE DRUG REACTION 
 
Although  all  new  drugs  undergo  clinical  trials  to  demonstrate  efficacy  and  
detect adverse effects, only the most common ADRs, will probably have been detected by 
the time the drug is marketed.  In addition, clinical trials are unlikely to have been carried 
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out on some groups of patients, such as the elderly or pregnant women. Pharmaceutical 
products must therefore be monitored after marketing to identify any more unusual, serious 
or delayed adverse effects. Adverse event detection systems have included manual methods 
and combination of both electronic and manual review process. 
 
1. Manual Methods 
 
Manual adverse event detection systems offer the ability to detect a wide array of 
adverse events, and with some methods, a substantial proportion of events. The systems 
described below are limited by either physician reluctance to use them or the resource 
requirements to maintain the system 
 
i. Provide voluntary reporting methods 
 
a) Incident reporting 
 
This is a cornerstone in safety initiative in the reporting and analysis of errors. 
Studies that have compared the rate of adverse event detection through incident reports to 
those detected by chart review have found that only 1.5% of adverse events and only 6% of 
adverse drug events are detected through incident reports. Voluntary reporting or incident 
reports still remain the mechanism that most institutions use to detect adverse events. 
[17]
 
 
Incident reports remain an attractive source of information for researchers because 
they are generally readily available however; problems with underreporting greatly 
limit their utility for patient safety research. Incident reports are underutilized because 
interruption in workflow, perception that completing a form will not result any 
improvement, lack of knowledge that an adverse event had occurred, and fear of exposing 
oneself to litigation. 
 
b) Prompted spontaneous reporting 
 
Some investigators have attempted to increase voluntary reporting through 
continuously prompting physicians to report errors or adverse events. Adverse events were 
reported through either electronic mail  or paper reports.  Although  voluntary reporting  
would  undoubtedly detect a broad range of adverse events, the current barriers to the 
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success of these systems require evaluating other methods for the detection that do not rely 
on physician reporting. 
 
ii. Provider involuntary reporting methods 
 
a) Chart Review: Most of the epidemiological evidence describing adverse medical events 
comes from several large studies that used chart reviews to detect adverse events. Charts 
undergo a two-phase screening process.  Initially a trained reviewer, usually a research 
nurse, examine charts for screening criteria and charts with one of these screening criteria 
then will undergo physician‟ s review. Physician reviewers made judgments on whether 
they believed an adverse event had occurred based on the information contained within the 
chart. When a physician reviewer was more than 50% confident that medical management 
resulted in the injury, an adverse event was considered to have occurred. Typically, either 
all or a fraction of the charts are reviewed independently by two physicians.  If the 
physician reviewers disagree on whether an adverse event occurred, the physicians will 
try to come to a consensus or involve a third party. 
 
 
Several problems exist with this methodology.  First, the positive predictive value of 
the initial  screening process  was  low  resulting in  the physician  reviewers  evaluating a  
high number of false positive charts.  Second, agreement between physicians is generally 
poor with respects to causality. 
 
b) Observers: Another method used to detect adverse events has been the use of trained 
observers. This approach has advantages over chart review in that is can be performed 
prospectively. A limitation of direct observation is that it can be an expensive method 
for error detection. 
[21]
 
 
c) Patient interviews: Outpatient charts are generally less data intense that inpatient 
charts with patient visit sometimes occurring only every few years.  As a result, many 
researchers have relied on patient interviews to detect adverse events in these settings. 
Recent survey evidence suggests that patients are probably a good potential source for 
adverse event detection. Patient interviews offer a novel potential source for adverse event 
detection yet, similar to using observers, require a substantial resource commitment.  
Furthermore, we are unaware of any studies that have attempted to “validate” patient 
reports of adverse events. However, patient observations concerning their care likely 
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uncovers adverse events that might not be detectable by other means and the approach 
warrants further study. 
 
2. Combined Modalities: 
To overcome the limitations of manual methods, several electronic methods for 
detecting adverse events have been evaluated. Advances in information technology, the 
increase in hospitals with integrated information systems, and ambulatory electronic 
medical records  now  offer  the  ability  for  institutions  to  automatically  detect  adverse  
events. Institutions with computerized event-monitors in place have been able to detect a 
greater number of adverse drug events when compare to their traditional systems. 
 
These are the methods for detecting adverse events that rely on both electronic and 
manual review process.  In general, these systems identify an electronically stored, 
generally coded “signal”, such as a laboratory abnormality, as screening criteria to identify 
charts for further review.   These systems generally require fewer resources to maintain 
than manual systems. However, as a result of poor specificities, much of these systems still 
require some form of manual review. 
 
3. The UK Yellow Card System: 
 
1. The Committee on Safety of Medicines (CSM) superseded the Committee on 
Safety of Drugs after the Medicines Act in 1968. The CSM is responsible for the 
assessment of new drugs before clinical trials and marketing have taken place. They 
also manage a spontaneous reporting system, which asks doctors and, more recently, 
pharmacists to report all suspected reactions to new products. Doctors and 
pharmacists are also asked to report all serious suspected reactions to established 
drugs, even if it is considered that the adverse effect is well recognized. 
Community pharmacists are requested to focus their  reporting  on  non-
prescription  medicines  and  both  licensed  and  unlicensed medicinal products.   In 
addition to the voluntary reporting of ADRs, pharmaceutical companies. 
2. A  system  capable  of  capturing,  retrieving  and  processing  the  Yellow  Card  
data  has  been developed, known as ADROIT (Adverse drug reaction on-line 
information tracking facility). This database allows rapid processing and analysis of 
the reports to identify any potential safety issues.   The Yellow Card scheme has 
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been successful in identifying both common and rare reactions and can also provide 
early warning of possible ADRs. 
 
Some drawbacks to spontaneous reporting systems, such as this do exist: 
 
 The incidence of a particular ADR is unknown owing to lack of information on 
the number of patients exposed to the drug.  A rough estimate can be calculated 
from the number of prescriptions dispensed. 
 There is considerable underreporting. 
 Some bias may be introduced if there is a tendency to report ADRs, which are 
well publicized. 
 ADRs, which are as yet unknown, are difficult to spot and so may be prone to 
underreporting. 
 
4. Anecdotal reports (Case reports): 
 
Case reports from individual clinicians are often published in the medical literature 
and may be important in detecting new ADRs.  These single reports usually require further 
studies to confirm an ADR, but some serious adverse effects have been brought to light by 
this mechanism.  Notable examples include the oculo muco cutaneous syndrome due to 
practolol and agranulocytosis caused by chloramphenicol. 
 
5.  Cohort studies (Prospective studies): 
 
A „cohort‟  of patients taking a specified drug is identified in this type of study.  
They are then monitored for adverse effects.  A control group is identified, which is drawn 
from the same population but is not taking the drug, in order to compare the incidence 
of adverse effects detected. It is fundamental that the two groups being compared are at 
equal risk of developing adverse effects, so must be of similar age, sex, overall morbidity 
and so on.  It is also crucial to include accurate data about drug exposure, i.e. the doses used 
and duration. 
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6. Case control studies (Retrospective studies): 
 
These studies involve a group of patients with symptoms, which it is suspected may 
be due to an ADR.  The patients are investigated to see if they have taken the drug in 
question. The prevalence of drug taking is compared to that of a control group who do not 
have the specified symptoms. Again the two groups must be comparable and, for the 
association to be made with confidence, accurate information about drug exposure is 
required. Due to the retrospective nature of these studies, there is reliance on adequate 
record keeping to provide this data. If patients themselves are used as the source of 
information about the amount, timing and duration of drug intake, then it is important 
to be aware of the difficulty in recalling such information, which could lead to bias.  
Another key difficulty in case control studies is the need to exclude patients who are at 
increased risk of developing the symptoms being studied. 
 
Despite their difficulties, these studies are useful for determining whether there is an 
association between a drug and adverse effect, but only once the relationship has been 
suspected. They cannot detect new ADRs. They are most often of value for testing 
hypothesis generated by spontaneous reporting. 
 
7. Record linkage studies: 
 
Patients medical records are used to match drugs prescribed with adverse effects 
experienced in record linkage studies. These studies may be particularly useful for 
identifying long-term adverse effects of drugs. Prescription event monitoring is an 
example of this type of study. This involves the identification of patients who have been 
exposed to a drug through dispensed prescriptions. The general practitioners with whom 
they are registered are then requested to submit details of all events occurring since drug 
exposure and details of stopping the drug if applicable. In this way events, which occur 
with greater than usual frequency, can be identified as potential ADRs and investigated 
further using case control or cohort studies. 
 
8.  Hospital-based population studies 
 
These are useful for determining the incidence of ADRs in hospitalized patients, or 
on admission to hospital.  Some use automatic signals from laboratory data and prescription 
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chart review in systematic programes. An example of this type of scheme is the Boston 
Collaborative Drug Surveillance Program, which involves selected hospitals in several 
countries. Due to the inclusion of all patients incidence rates for ADRs can be calculated 
and causality assessment is improved; however the studies are expensive. 
 
9.   International ADR reporting: 
 
The   World   Health   Organization   Collaborating   Centre   for   International   
Drug Monitoring was established in 1968.   The centre collects spontaneous ADR reports 
from participating national centres and aims to increase early recognition of new and 
unexpected ADRs. By combining reports from many countries all over the world, very 
rare adverse reactions can be detected. 
 
10. Patient-centered studies 
 
Post  marketing  surveillance  of  medicines  can  be  carried  out  using  information 
supplied by patients.   This is feasible for both prescribed and non-prescription medicines. 
Questionnaires are supplied to patients or telephone interviews conducted which focus on 
the occurrence of symptoms, which could be ADRs. Various methods can be used to 
identify cohorts of patients, such as patient medication records (PMRs) in community 
pharmacies or general practice databases. For non-prescription drugs, patients who 
purchase these from community pharmacies can be included in studies. These systems have 
been piloted in Canada, the USA and Scotland and may provide a valuable method of 
detecting ADRs, which complement other systems. 
 
11. Non-prescription medicines 
 
Since prescription medicines supplied through the NHS are recorded in medical and 
pharmacy records, their use can be traced and associations made with symptoms, which 
could be ADRs. However non-prescription medicines are obtainable from many outlets, 
including pharmacies, and there is no requirement for these purchases to be recorded in 
either medical or pharmacy records.  It is good practice to include these records on PMRs 
when purchases are made from pharmacies and, for patients who take multiple prescription 
medicines; this provides a valuable source of information, which can be used to prevent 
ADRs arising from duplication or interactions. 
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Community pharmacists have an important role to play in reporting ADRs to non- 
prescription medicines, which are currently seriously underreported. By establishing 
computer records of non-prescription product purchases and therefore defining a population 
of users of particular products, it would be feasible to involve pharmacists in post marketing 
surveillance studies such as event monitoring, case control or cohort studies. 
 
PREVENTIVE MEASURES FOR ADVERSE DRUG REACTION 
 
Comprehensive and ongoing ADR monitoring, evaluating and  reporting programs 
need to be initiated that should focus on the assessment of incidence, prevalence, category, 
severity, preventability, costs and burdens of adverse drug reactions. This will help ensure 
that patients receive safe medicines and mortality or morbidity due to ADRs is considerably 
reduced. The most ideal way to manage ADRs is to prevent its occurrence in 
predictable cases. However, if it has occurred, therapeutic measures become necessary. 
 
Preventive measures are: 
 
1. Never use any drug unless there is good indication. If the woman is pregnant do not 
use a drug unless the need is imperative. 
2. Choose an alternative therapy of relative efficacy and safety. Eg: if patient is 
allergic to penicillin, choose other alternative like amoxicillin. 
3. Using a prophylaxis to other drugs to prevent future ADRs. Eg: penicillin 
should be injected subcutaneously for skin test to prevent the occurrence of 
anaphylaxis. 
4. Allergy and idiosyncrasy are important causes of adverse drug reactions. Ask if 
the person had previous reactions. There may also be family history of adverse 
reactions to drugs that share a common characteristic indicative of inherited 
disorder. (Eg: Glucose phosphate dehydrogenase deficiency). 
5. Ask  if  the  person  is  already  taking  other  drugs  including  self  medication  
drugs, otherwise interactions may occur. 
6. Age and hepatic or renal impairment may alter the metabolism or excretion of 
drugs so that much smaller doses may be needed. Genetic factors may also be 
responsible for variations in metabolism. 
7. Prescribe a few drugs as possible and give clear instructions to elderly patients or 
any patient likely to misunderstand complicated instructions. 
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8. Whenever possible use a familiar drug. New drugs are particularly alert for or 
unexpected events. 
9. If serious adverse events are liable to occur, warn the patient. 
10. Implementation  of program  designed  to  educate patient  about  their medication  
and potential for ADRs. 
Documentation of ADRs is necessary to avoid re exposure
[15]
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REVIEW OF LITERATURE 
  
 
Inocencia  Martanez-Mir  et  al.,  (1999) carried  out  a  prospective  study  events  
monitoring scheme was fused a total of 512 successive admissions to two medical paediatric 
wards [47 beds] were analyzed. The hospital records were screened daily during two 
periods [summer 105days and winter 99 days] and adverse clinical events observed were 
recorded. A total of 282 events were detected ; of these 112 were considered to be 
manifestation of ADR's. The cumulative incidence was 16.6%,  no differences being 
observed between periods. Risk was found to be significantly higher among girls 
compared with boys [RR=1.66,95% CI 1.03-2.52] the gastrointestinal system was most 
frequently effected. The therapeutic group most commonly implicated was anti infective 
drugs and vaccines [49.5%]. The ADR's were mild or moderate in over 90% of cases. The 
consistent relationship was noted between the number of drugs administered and incidence of 
ADR.[18] 
 
K.A Oshikoya et  al.,  (2007) studied on adverse drug reaction in children found out 
that with prompt recognition and reporting will go a long way in minimizing the incidence of 
ADRs.  The  most   commonly  affected  organ   systems   are  the  skin   and   appendages. 
Stevensjohns syndrome and toxic epidermal necrolysis are the most severe dermatological 
manifestations of ADRs. The key to appropriate management of adverse drug reactions is 
prevention and prompt recognition. However prevention is the best way to avert ADRs. The 
greatest hope lies in the future of predicting ADRs by genetic determination before 
drug recommendations in children[19]. 
 
Bruce C Carleton (2007) studied on adverse drug reactions in children. It was a 
retrospective analysis of 1193 suspected ADRs reported to Health Canada (January 1998 
- May 2002). 58.6% of ADRs were for children over 13 years. 61% of reports were 
defined by Health Canada as serious. Case outcomes include: death (n=41) and recovered 
with sequelae (n=14). 4 reports of interacting drugs had fatal outcomes. Drugs most 
frequently cited include: isotretinoin (n=56), paroxetine (n=42), methylphenidate (n=41), 
amoxicillin (n=40), and valproic acid (n=32). Most frequent reaction descriptors include: 
psychiatric disorders (isotretinoin and paroxetine) and nervous system disorders (valproic 
acid, bupropion and carbamazepine). Causal links between suspected ADRs and clinical 
outcomes have not been established. They concluded that current ADR reporting is 
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insufficient to improve patient safety.[20] 
 
Jennifer et  al.,  (2006) Le, Pharm D studied on adverse drug reactions among 
Children over a 10- Year Period. It was a retrospective cohort study of paediatric patients 
who experienced an adverse drug reaction between January 1,1995, and December 31, 2004, 
was conducted at a community-based tertiary care, children's teaching hospital. They found 
out that a   total of 1087 adverse drug reactions were reported; the overall incidence was 
1.6%. The severity of most adverse drug reactions was low (levels 1–3: 89%; high levels 4–
6:11%). Adverse drug reaction with low severity were significantly more common in both 
the general paediatric unit and the NICU.Adverse reactions resulting from use of antibiotics 
(particularly penicillins, cephalosporins, and vancomycin) were usually mild. In contrast, 
adverse drug reactions rated high in severity were significantly more common among 
reactions that led to hospital admission or occurred during surgery and among certain drug 
classes, including anticonvulsants and anti neoplastic agents. Adverse drug   reaction were 
reported by pharmacists (89%), nurses(10%), and physicians (<1%). Although   
documentation of physician notification occurred for 93% of adverse drug reactions, 
only29% of cases were documented in the patient's medical chart,13% included follow-up 
education for individuals involved, and10% were updated in the allergy profile of the 
hospital computer system. They concluded that measures to improve detection and reporting 
of adverse drug reactions by all health care professionals should be undertaken, to enhance 
our understanding of the nature and impact of these reactions in children[21]. 
 
Seyed Bahram Mir Saeed Ghazi et  al.,  (2007) studied the adverse Drug Reactions 
as a Cause for Admissions to a Children’s Hospital. They aimed to investigate the 
adverse drug reactions (ADR) in paediatrics and determine the predominant symptoms of 
adverse drug reactions in children. This case series study was carried out at the Bahrami 
Pediatric Hospital, Tehran where the files of 25 admitted patients with the diagnosis of 
adverse drug reaction 1998 to 2005 were studied. The average age was 4.6 (±3.7) years and 
symptoms of adverse drug reactions were observed12.6 (±14.3) days after initiation of the 
drug intake. Skin rash was seen in all patients more in form of maculopapular rash followed 
by urticaria. Arthralgia was the next common symptom observed in 44%of patients. The 
common abnormal laboratory data was high erythrocyte sedimentation rate which was seen 
in 40% of patients. The most common ingested drugs were phenothiazine and sulfasalazine 
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(eachof them seen in 28% of patients) followed by penicillin (16%), furazolidone (16%), 
cephalosporins (4%) and valproic acid (4%). In 28% of patients poly-pharmacy was 
responsible for ADR. They concluded that awareness of the problem, observation of poly-
pharmacy and potential drug-drug interactions, and  continuous  re-evaluation  of  the  
ongoing  individual  pharmacotherapy  is  important, especially in children, to reduce  
ADRs. [22] 
 
A Circo-Begovic et  al.,  (1989) carried out a study on intensive monitoring of 
Adverse drug reactions in infants and preschool children in paediatric outpatient unit 
covering the town of Karlovac was performed over a period of time of three  months. 
Data were obtained by physical examination of children and the history given by their 
parents. In all 2359 children were examined. ADR was recorded in 63 children and were 
reported to the national ADR monitoring centre in Zagreb using the algorithm of Hutchinson 
et al [1979], all ADR were classified as ''definite'', ''probable'', ''possible'' and ''unlikely''. 
Drugs were prescribed in 97.3% of children, 60.24% received an anti microbial agent and an 
antipyretic was given to 1878 children, mostly paracetamol. ADR were most frequently 
caused by antibiotics[49 reactions to penicillin V, and 15 to amoxycillin] and secretolytics 
[7 reactions]. ADR were followed by complete recovery and not a single child was 
hospitalized because of ADR.[17] 
 
Pirmohamed et  al.,  (2004) carried out  a prospective  observational  study over  a 
6-month period.  18,820 people admitted to emergency departments or acute medical or 
surgical units were screened for ADRs. The ADR was directly responsible for 80% of these 
cases (95% CI 78 to 82, n = 980).   People with ADRs used 4% of hospital beds (median 
stay 8 days, projected annual cost to NHS of £466 m).  The overall fatality rate due to an 
ADR was 0.15% (28/18,820 individuals).   Gastrointestinal bleeding was the most common 
ADR. Drugs commonly causing ADRs were aspirin NSAIDs, diuretics and warfarin.   Drug 
interactions accounted for 16.6% of ADRs.  The authors concluded that adverse drug 
reactions account for a high number of admissions, most of which are avoidable[23]. 
 
M  I Kidon,  et  al.,  (2004) conducted  a  study  on  adverse  drug  reactions  in  
Singaporean children. They aimed to define the prevalence and characteristics of reported 
drug allergies in hospitalized children in Singapore. It is a retrospective case control study 
was performed through the hospital’s inpatient electronic medical record (EMR) for the 
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period of August 2002 to December 2002. Of the 8437 patients hospitalized during the study 
period, reports of previous ADRs were found in the records of 222 patients. The mean age 
of the patients was 7.4 years, range 2 months to 17 years (95 percent confidence interval [CI] 
6.3 - 8.4). There were  146  males  and  160  Chinese.  The  most  commonly- involved  
medications  were betalactum antibiotics (45 percent) and non steroidal anti-inflammatory 
drug (18.5 percent). Compared to the control group, children with a reported ADR were 
more likely to be older, with a mean age of 7.4 years versus 4.6 years (p-value less than 
0.001), male (odds ratio [OR] 1.7, 95 percent CI 1.2-2.4), of Chinese descent (OR 1.8, 95 
percent CI 1.5-5), have an associated chronic illness (OR 3.5, 95 percent CI 2.5-5), and a 
diagnosis of asthma (OR 2.7, 95 percent CI 1.7-4.5). They concluded that in paediatric 
inpatient population, the risk of reported ADRs increases with age, male gender, Chinese 
descent and the presence of chronic disease. The major drugs involved are betalactam 
antibiotics and non-steroidal anti- inflammatory drugs.[24] 
 
BA King et  al.,  (2003) studied adverse skin and joint reactions associated with oral 
antibiotics in children. It was a 12 month retrospective study. To describe clinical course of 
children with cefaclor related serum sickness like reactions and compare these with cases 
reported to the ADRs advisory committee. They found out that 150 children occurs adverse 
skin reaction, 70 after cefaclor alone, 10 after cefaclor in combination with other antibiotics 
and 70 after other antibiotic courses. SSLR occurred in 44 children; 32 after cefaclor alone, 5 
after cefaclor in combination with other antibiotics and 7 after other single antibiotics.In 
children with cefaclor SSLR, otitis media was most common indication, other had viral 
illnesses. Prolonged sequele in 4 children. 60 reports of paediatric cefaclor SSLR were 
made to ADRAS during study period and none originated from PMHED.[25] 
 
 
Helene Peyriere et  al.,  (2003) studied adverse drug events associated with hospital 
admissions in saint-eloi hospital. It is a prospective study of 48 days to increase the 
knowledge based on the frequency, causality and avoidability of ADR events as a cause for 
admission in internal medicine or when occurring during hospitalization. A total of 156 
patients (70men and 86 women) were included. The investigators put forward their results as 
patients mean age SD was 66.5+_ 18.1 years and mean length of stay was 13.2 +_9 days. 38 
ADEs occurred in 32 patients. In 15 cases, ADEs were identified as the reason for 
admission, but were not the cause of admission. The most frequent ADEs involved 
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neurologic (23.6), renal (15.7%) and hematologic systems. Among these ADEs, 22 were 
considered avoidable (57.9%); 20 of these were associated with therapeutic errors. Patients 
with ADEs stayed longer in the hospital and took more drugs both before and during their 
hospital stay. The authors concluded that most of the ADEs observed in their study were 
avoidable. The risk/ benefit ratio of administered drugs could be improved with better 
knowledge of the patients medical history and risk factors of ADEs[26]. 
 
Samuel et  al.,  (2003) made an attempt to introduce an ADR monitoring programme 
at two hospitals and an outpatient skin specialty clinic in South India to evaluate the 
programme. They introduced an ADR monitoring programme in three participating 
centres and ADRs were documented and analyzed over a period of six months.   In total, 
152 ADRs were documented.  The percentage of patients with a reported ADR at each of the 
three centers was 3.5, 3.7 and 2.3.  Using Naranjo’s probability scale, 25.7 per cent of 
ADRs were categorized as “probable” and 74.3 per cent as “possible”. Of the ADRs 
reported in the two hospitals, 31.1 per cent related to unplanned medication-related hospital 
admissions and 68.9 per cent occurred during the hospital stay.  Antibiotics (32.2 %), 
psychotropic drugs, steroids and non- steroidal anti-inflammatory drugs (11.8% each) were 
the most common drugs that caused ADRs.  Occurrence of ADRs seemed to be similar to 
those reported in the developed world, with the exception of the proportion of severe ADRs 
(25%), which was higher than reported elsewhere in published studies.[26] 
 
Jutta Weiss  et  al.,  (2012) studied ADRs in 1 ward and assessed whether a general 
approach, e.g. by a computerized monitoring system, to detect ADRs in children feasible and 
likely to yield  a higher rate of  early detected ADRs.  The aim  was  to  assess  the 
usefulness  of a computerized monitoring system before implementing costly adaptations .It 
is a 8-month prospective study was conducted at a 10-bed paediatric isolation ward of the 
University Hospital. A total of 68 ADRs were detected in 46 of 214 patients by the 
pharmaco epidemiological team. Thirty-four ADRs (50%) were detected by the staff 
physician, and 27 (40%) were detected primarily by analyzing   laboratory parameters. 
Antibiotics-associated ADRs(50%) predominated, followed by glucocorticoids (16%), 
tuberculostatic(4%), and immunosuppressive agents (4%). In 5 cases, an ADR was 
responsible for the prolongation of hospital stay, and in4 children, the ADR was responsible 
for hospitalization. They concluded that detection rate of ADRs would almost be doubled by 
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a computerized monitoring system analyzing laboratory data. Implementation of a computer 
monitor system that automatically generates laboratory signals may help to identify ADRs 
in children, and to reduce morbidity and hospital stay, as well as costs.[28] 
 
Lazarou, J et  al.,  (2001) studied the incidence of adverse drug reactions in 
hospitalized patients. Their aim was to estimate the incidence of serious and fatal adverse 
drug reactions (ADR) in hospital patients. Four electronic databases were searched from 
1966 to 1996. of 153, they selected 39 prospective studies from US hospitals. Data 
extracted independently by 2 investigators were analyzed by a random-effects model. The 
overall incidence of serious ADRs was 6.7% (95% confidence interval [CI], 5.2%-8.2%) and 
of fatal ADRs was 0.32% (95% Cl, 0.23%-0.41 %) of hospitalized patients. We estimated 
that in 1994 overall 2 216 000 (1721000-271 000) hospitalized patients had serious ADRs 
and 106000 (76000-137000) had fatal ADRs, making these reactions between the fourth and 
sixth leading cause of death. They concluded that the incidence of serious and fatal ADRs 
in US hospitals was found to be extremely high.[29] 
 
Asawari L Rout et  al.,  (20012)  carried out a prospective observational study for the 
duration of 8 months amongst medicine inpatients of a teaching hospital. Preventability, 
Predictability and Seriousness were assessed for each suspectedADR. In addition to this, 
effect of length of stay on happening of an ADR was also assessed. Our finding showed 
about 34% ADRs were “Definitely preventable”, 21% were “Probably preventable”while 
remaining 45% were “Not preventable”. 72.71% of the reactions prolonged the 
hospitalization of patients whereas 25.18% of the reactions required intervention to prevent 
permanent damage and only 2.10% of the reactions were life threatening. Almost 69% ADRs 
deemed predictable. Although ADRs encountered in the study are non serious and not 
preventable, management of such ADRs through therapeutic interventions would be 
beneficial in better patient outcome[30]. 
 
Jha N et  al.,  (2007) carried out an analytical cross sectional study  designed from 
May 2007 to September 2007 in which prevalence of ADR was calculated. A total of 37 
cases of ADRs were taken from 4287 patients and 10% of the remaining population without 
ADRs i.e. 425 out of 4250 patients was selected randomly. Prevalence of ADR in this study 
was 0.86% and male to female ratio was 0.85. 54.1% were female and 45.9% were male (P = 
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0.65). The highest percentage of ADRs were seen in adult patients, however the difference 
was statistically not significant. Maximum numbers of ADRs were reported from skin, 
35.13% followed by GIT, 29.72% and then from CNS, 18.91%. Anti-infectives were 
associated with maximum number of ADRs followed by IV urograffin. Rashes, 35.13% were 
the most common type of ADRs reported followed by vomiting, 13.51% and then dizziness 
which was 10.81%. Regarding the outcomes attributed to ADRs, one patient died due to 
ADR caused by dapsone and 15 cases got hospitalized due to ADRs. For causality of ADRs, 
according to Naranjo algorhythm scale, 35% of reactions were assessed to be probable, 32% 
as possible and 19% were definite. Similarly, for severity assessment, 54% reports were mild, 
35% were moderate and 10.81% were severe.  Prevalence of ADR in this study was 0.8% 
which is similar to other studies in other countries. All the ADRs were not toxic reactions and 
they were unpredictable[36]. 
 
A summary analysis of three descriptive studies of significant adverse drug 
events (ADEs) was conducted by William.  Case reports of ADEs published in Clinical 
Alert during 1976-97 were the source of information on ADEs.  William’s studies revealed 
that during the 21-year period, 1520 significant ADEs were reported, 29% of which resulted 
in death, 15% in permanent disability, and 56% in life threats.  Event types were distributed 
as adverse drug reactions (52%), allergic drug reactions (25%), medication errors (15%), and 
drug interactions (8%).  The drug categories most commonly involved in ADEs were 
central-nervous-system agents, antimicrobials, antineoplastics, and cardiovascular agents.    
The nervous, hematopoietic, cardiovascular, and respiratory systems were affected the most.  
Overall, 52% of  the  cases  were  judged  to  have  been  preventable;  of  these,  a  
pharmacist  could  have prevented 50%. 
 
A study conducted by G.Stavreva et  al.,  (2011) also revealed the predominance of 
Cephalosporins whereas fluoroquinolones were most accounted in a study conducted by 
M.M Hussain et al. while Vancomycin and Penicillins were most frequent  in the  study 
of R. Priyadharsini et al.[31,32] 
 
Palaniswami S, et  al.,  (2009) carried out a prospective observational study for a 
period of 6 months in an inpatient and outpatient department of a south Indian hospital. In a 
total of 96 patients, nearly 59 percent of patients were male it indicates that the prevalence of 
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ADRs is more in men than in women. 42.71 percent (41) ADRs were found in the age group 
between 41 and 60 shows that ADRs in this locality hospital is more in these age group 
peoples. Most of the ADRs were treated by withdrawing the offending drug (81.25%). WHO 
probability assessment scale shows 42.71% (41) cases were probable, of which 27.08% (26) 
were male and 15.63% (15) were female. 5.21% (5) ADR were unclassified or in assessable. 
Naranjo’s causality assessment scale shows 5.21% (5) of ADRs were Definite, 90.62% (87) 
of ADRs were probable, and 4.17% (4) of ADRs were possible. Many of the ADRs were 
reported from Neurology department (40.63%), it is followed by internal medicine 
department (20.83%) and other departments[37]. 
 
Analysis of the type of reported ADRs according to Rawlin and Thompson revealed 
Type A predominance. This result is in line with the study conducted by K.A Oshikoya et al 
and G.Starveva et al but in another study by Suthar J.V and Desai S.V, all the reported 
reactions were Type B reactions. Type A reactions are dose related and thus were preventable 
from their known pharmacology and therefore all of them were potentially avoidable. 
R.G Eva states that Type B reactions comprise approximately 10-15% of all ADRs and 
include hypersensitivity drug reactions.[33] 
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AIM AND OBJECTIVES  
 
 To detect and analyze adverse drug reactions of anti-
infective agents in children between 1-10years of age. 
 To detect the incidence rate of adverse drug reactions of anti infective 
agents in children between 1-10years of age. 
 To study the extend of incidence and severity of ADR's in our hospital. 
 To assess the casualty of ADR caused by anti infective agent in childrens. 
 
As the number of formulations available in Indian market has crossed more than 1 
lakh, the process of choosing  and prescribing the most suitable drug  for individual patients, 
with lesser adverse effects is becoming increasingly complex  for the physicians. Most 
studies of adverse reactions to drugs in children have been based on subjects who received 
drugs in hospital or at home shortly before admission. 
 
As hospital drug use is very different from outpatient service, the incidence and 
profile of adverse reactions might also be expected to vary. Intensive monitoring of pediatric 
sideeffects has rarely been done. The purpose of the present study was to monitor the 
incidents and causes of ADR in children treated with anti-infective agents in a general 
pediatric inpatient unit at CGM Health care Sree Shanmughavilasam Hospital.  
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PLAN OF WORK 
 
The present dissertation work was planned to determine the adverse drug reaction of 
anti-infective agents in paediatric patients. The work was planned to conduct in C.G.M 
Healthcare Sree Shanmughavilasam Hospital, Punalur . 
 
The plan of work includes: 
 
1. Submission of protocol for approval from Institutional ethical committee. 
2.  Designing data collection form. 
3. Collection of case histories of the patient with cutaneous  ADRs. 
4. Collection of consent from patients care taker. 
5. Evaluation of collected data. 
6. Designing casuality assessment Naranjo Algorithm scale 
7. Assessment of level of severity of ADRs using Hartwig scale. 
8. Data analysis with the help of computer using Microsoft Excel 2007. 
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MATERIALS AND METHODS 
 
A prospective spontaneous reporting study involving active methods [pharmacist 
actively looking for suspected ADR's] and passive methods [stimulating prescribers to 
report suspected ADR] was carried out in a general paediatric inpatient department of 
C.G.M Healthcare sree shanmughavilasam Hospital, Punalur between February and July 
2013. A total number of 100 paediatric patients will be included in the study. All the 
suspected ADR's due to anti-infective medication in paediatric inpatient aged between 1 
to 10 years were noted and reported by various departments of this hospital are included in 
this study. Drug reactions that results due to medication errors, use of alternative systems of 
medicines, and departments like dentistry, surgery, oncology  etc are excluded. The data for 
the study was taken from case sheets, investigation reports of patients who had experienced 
an ADR, personal interviews with patients or patient's attendant, past history of medication 
use, personal interviews with reporting persons or clinicians.  
 
The causality assessment of the reported ADR's was carried out using "Naranjo 
causality assessment scale". The Naranjo Algorithm, the drug reaction can be classified as 
definite, probable, as possible. The modified Hartwig and Siegel Scale classifies severity of 
ADR as mild, moderate or severe with various levels according to factors like requirements 
for change in treatment, duration of hospital stay, and the disability produced by adverse 
drug reaction. 
 
METHODOLOGY 
STUDY DESIGN 
 
It is a prospective spontaneous reporting study. 
 
STUDY CENTRE 
 
C.G.M Health care Sree Shanmugha vilasam Hospital,Punalur, Kollam,Kerala. 
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STUDY POPULATION 
 
Paediatric in patients aged between 1-10 years treated with anti infective agents. 
 
STUDY PERIOD 
 
6 Months 
 
SAMPLE SIZE 
 
100 
 
STUDY CRITERIA 
 
INCLUSION CRITERIA 
 
1) Paediatric patients, aged between 1-10 years, treated with anti infective agents 
2) Both  male and female paediatric inpatients treated with antibiotics, anti viral, anti 
fungal drugs etc. are included in the study. 
3)  
EXCLUSION CRITERIA 
 
1) Drug reactions that results due to medication errors, use of alternative systems of 
medicines, departments like Dentistry, Oncology etc are excluded from the study. 
2) Terminally ill patients. 
3) Those who did not consent to be interviewed. 
 
INCLUSION CRITERIA 
 
1)  Paediatric patients, aged between 1-10 years, treated with anti infective agents 
2)  Both  male and female paediatric inpatients treated with antibiotics, anti 
viral, antifungal drugs etc. are included in the study 
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EXCLUSION CRITERIA 
 
1)  Drug reactions that results due to medication errors, use of alternative systems 
of medicines, departments like Dentistry, Oncology, surgery etc are excluded 
from the study. 
2)  Terminally ill patients. 
 
3)  Those who did not consent to be interviewed. 
 
 
STUDY VARIABLE 
 
 
ADR  caused  by  anti  infective  agents  in  paediatric  inpatients  between  age  
group 1-10   years. The suspected ADRs produced by commonly used antibiotics like 
ampicillin, amoxicillin, chloramphenicol, azithromycin,  erythromycin, tetracycline etc. 
Then  antiviral drug acyclovir, anti fungal drug fluconozol etc was monitored by this study. 
 
The data for the  study was taken from  case sheets, treatment  charts, 
investigation reports  of  patients  who  had  experienced  an  ADR,  personal  interviews  
with  patients  or patient’s attendant etc. 
 
Analysis of the results: The data collected during the period are to be statistically 
analyzed for the following parameters. 
 
-   The total number of ADRs reported. 
 
-   Age groups and gender of the patients 
 
-   Assessment of causality based on ‘ Naranjo Scale’ 
 
-   Assessment of level of  severity of ADRs using ‘Hart wig Scale’ 
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RESULTS 
 
During the study period, 12 ADRs of anti infective agents were reported. Table 1 shows the list 
of reported ADRs. 
 
LIST OF ADRs REPORTED DURING THE STUDY PERIOD  
Table 1 
 
 
SL 
NO 
NAME GENDER AGE SUSPECTED DRUG ADR REPORTED REASON FOR 
ADMISSION 
1 ISHANI F 3 YR AZITHROMYCIN DIARRHOEA,EPIGAST
RIC DISTRESS 
BRONCHITIS 
2 NUMAN M 4.5 
YR 
AMOXYCILLIN FATIGUE,ABDOMINA
L PAIN,VOMOTTING 
RHEUMATIC 
FEVER 
3 ADARSH M 3.5 
YR 
AMPICILIN LOOSE 
STOOLS,ABDOMINAL 
PAIN 
CHOLERA 
4 ANJU F 4 YR CEFIXIME DISPEPSIA,SEVERE 
HEAD ACHE 
BRONCHITIS 
5 VINDHYA F 4 YR AMIKACIN DECREASED GFR RENAL 
INFECTION 
6 PREETHI F 5 YR CEFTRIAXONE THROMBOPHLEBITIS,
CANNULA SITE 
INFLAMMATION 
MENINGITIS 
7 ARUN M 2 YR BENZYL PENCILLIN LOCAL IRRITATION, 
MILD RASH 
BRONCHO 
PNEUMONIA 
8 NIGKILA F 4 YR METRONIDAZOLE EPIGASTRC 
DISTRESS,VOMITTIN
G 
AMEBIASIS 
9 MELVIN M 7 YR VANCOMYCIN MACULO PAPULAR 
RASHES ON FACE 
AND NECK 
MENINGITIS 
10 MIDHUN M 5 YR BENZYL PENCILLIN LOCAL 
REACTION,HYPERSEN
SITIVITY 
BRONCHO 
PNEUMONIA 
11 DIVYA F 6 YR CIPROFLOXACIN ITCHING,SKIN 
RASHES 
THYPHOID 
FEVER 
12 MANJU F 4 YR CLOXACILLIN DIARRHOEA,EPIGAST
RIC DISTRESS 
UPPER 
RESPIRATORY 
TRACT 
INFECTION 
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TABLE : 1 
 
TOTAL NUMBER OF ADRs DUE TO ANTI INFECTIVE AGENTS 
 
 
 
Total number of subject (N) 100 
Number of reported ADRs 12 
 
 
 
REPORT: 
 
Among 100 paediatric patients treated with anti infective agents, 12 ADRs 
were reported and the incidence rate was found  to be 12%. 
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FIGURE : 1 
 
TOTAL NUMBER OF ADRs DUE TO ANTI INFECTIVE AGENTS 
 
 
 
 
 
 
88% 
12% 
Total no. of subjects(N) 100
No. of reported ADR(n) 12
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TABLE : 2 
 
NUMBER OF ADRS REPORTED BY ACTIVE OR PASSIVE METHOD 
 
 
ADRs reported by Number Percentage 
Active method 7 58.30% 
Passive method 5 41.66% 
Total number of ADRs reported =12 
 
 
REPORT: 
 
Out of 12 reported ADRs ,7 (58.30%) was reported by active method and 5 (41.66%) by 
passive method. 
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FIGURE : 2 
 
NUMBER OF ADRS REPORTED BY ACTIVE OR PASSIVE METHOD 
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TABLE : 3 
 
DIVISION OF ADRs BASED ON GENDER OF THE PATIENTS 
 
 
 
Sex Number Percentage 
Male 5 41.66% 
Female 7 58.34% 
 
 
REPORT: 
 
The incidence rate was found to be more in Females 7 (58.34%) and less in male 
paediatric patient 5 (41.66%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATIONS AND RESULTS 
 
Ultra college of pharmacy, Madurai  Page 46 
 
FIGURE : 3 
 
DIVISION OF ADRs BASED ON GENDER OF THE PATIENTS 
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TABLE : 4 
 
THERAPEUTIC CLASS OF ANTI INFECTIVE AGENT 
 
 
 
Class of anti infective agents Number percentage 
Penicillins (Ampicillin,Cloxacillin, 
Amoxycillin,Benzyl penicillin) 
5 41.66% 
Glycopeptide (Vancomycin) 1 8.33% 
Cephalosporin (Cefixime,Ceftriaxone) 2 16.66% 
Aminoglycosides (Amikacin) 1 8.33% 
Macrolides (Azithromycin) 1 8.33% 
Fluroquinolones (Ciprofloxacin) 1 8.33% 
Antibnacterial/amoebicide (Metronidazole) 1 8.33% 
 
 
REPORT: 
 
The  antibiotic  class  mostly  affected  with  ADRs  in  paediatric  inpatients  was 
penicillins 5 (41.66%) followed by cephalaosporin 2 (16.66%) and macrolides 1(8.33%). 
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FIGURE : 4 
 
THERAPEUTIC CLASS OF ANTI INFECTIVE AGENT 
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TABLE : 5 
 
ORGAN SYSTEM AFFECTED DUE TO ADRs 
 
 
 
 
Organ  system Number Percentage 
GIT 7 58.33% 
Skin 3 25.00% 
Nephro toxicity 1 8.33% 
CNS 0 0% 
Respiratory 0 0% 
Haematological 0 0% 
Local reaction 1 8.33% 
 
 
REPORT: 
 
Organ system most affected by ADRs due to antibiotics was found to be 
GIT 7 (58.33%) followed by skin 3 (25.00%) and .local reactions 1 (8.33%). 
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FIGURE : 5 
 
ORGAN SYSTEM AFFECTED DUE TO ADRs 
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TABLE : 6 
 
CLASSIFICATION OF ADRs 
 
 
 
 
Type of ADRs Number Percentage 
Type A 10 83.33% 
Type B 2 16.66% 
 
 
 
REPORT: 
 
Type A reactions 10 (83.33%) was most common compared to type B 2 (16.66%). 
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FIGURE : 6 
 
CLASSIFICATION OF ADRs 
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TABLE : 7 
 
 ROUTE OF ADMINISTRATION OF ANTI INFECTIVE AGENTS THAT CAUSE 
ADRs 
 
 
 
 
ROA Number Percentage 
Oral 6 50.00% 
Parenteral 6 50.00% 
 
 
REPORT: 
 
Among 12  reported ADRs 6 (50.00%) was due to oral route of administration 
and 6 (50.00%) parental. 
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FIGURE : 7 
 
ROUTE OF ADMINISTRATION OF ANTI INFECTIVE AGENTS THAT CAUSE 
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TABLE : 8 
 
FATE OF SUSPECTED DRUGS 
 
 
 
 
Fate of suspected drug Number Percentage 
Drug withdrawn 5 41.66% 
Dose altered 4 33.33% 
No change 3 25.00% 
 
REPORT: 
 
In 5 (41.66%) cases the suspected drug was withdrawn  while no change was made 
with suspected drug in 3 (25.00%) and the dose was altered in 4 (13.33%) cases. 
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FIGURE : 8 
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TABLE : 9 
 
OUTCOME OF ADRs 
 
 
 
 
Management of ADRs Number Percentage 
Recovered 11 91.66% 
Fatal 0 0% 
Unknown 1 8.34% 
 
 
REPORT: 
 
Out of 12 reported ADRs, 11 (91.66%) patients recovered, and there is no fatal 
 
ADRs, 1 (8.34%) cases were found to be unknown. 
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FIGURE : 9 
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TABLE : 10 
 
TREATMENT GIVEN 
 
 
 
 
Treatment given Number Percentage 
Specific 2 16.66% 
Symptomatic 9 75.00% 
Nil 1 8.33% 
 
 
 
REPORT: 
 
Specific treatment was given in 2 (16.66%) cases while 9 (75.00%) cases 
required symptomatic treatment and no treatment was given for 1 (8.33%) cases. 
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FIGURE : 10 
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TABLE : 11 
 
LEVEL OF SEVERITY OF REPORTED ARDs 
 
(USING MODIFIED HART WIG AND SIEGEL SCALE) 
 
 
 
 
Severity Number Percentage 
Mild 4 33.34% 
Moderate 8 66.66% 
Sever 0 0% 
 
 
 
 
REPORT: 
 
Moderate  reactions  accounted  for  8 (66.66%)  followed  by  mild  4  (33.33%)  
and  no reactions were found to be severe. 
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FIGURE : 11 
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TABLE : 12 
 
CAUSALITY ASSESSMENT OF ADRs 
 
(USING NARANJO SCALE) 
 
 
 Number Percentage 
Definite 0 0% 
Probable 6 6.25% 
Possible 57 59.37% 
Unlikely 37 38.54% 
 
 
REPORT: 
 
Using Naranjo scale for causality assessment 6 (6.25%) was probable,57 (59.37%) were 
possible, 0% definite, and 37 (38.54%) were unlikely. 
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FIGURE : 12 
 
CAUSALITY ASSESSMENT OF ADRs 
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RESULT 
 
 
During the study period, a total of 12 adverse reactions of anti infective agents were 
reported among paediatric patients aged between 1 to 10 years among 100 peadiatric 
inpatients; The incidence rate of antibiotic adverse reactions was found to be 12%.And 
about 5 (41.66%) male paediatric patients predominated over female 7 (58.34%)   in ADR 
occurrence. This study was  a  prospective spontaneous   reporting study , in which  7 ADRs 
were reported by active methods and  5 were by passive methods ( reported by 
doctors).Results revealed that GIT 7 (58.33%)   was   the most affected organ system by 
adverse reactions due to antibiotics followed by skin 3 (25.00%).The Antibiotic class mostly 
affected with ADR in paediatric inpatients was pencillins 5 (41.66%) followed by 
cephalosporin 2 (16.66%).Of the reported ADRs, Type A 10 (83.33%) was most common  
compared to  type B 2 (16.66%) reactions according to the ADR classification by Rawlin 
and Thomson. 
 
In 5 (41.66%) cases the suspected drug was withdrawn while no change was 
made with the suspected drug in 3(25.00%) and the dose was altered in 4 (33.33%) cases. 
From this study, it was found out that there was recovery from ADRs  in a total of 
11(91.66%) patients although   0%   had fatal   ADRs. Out of this 1 (8.34%) case was 
found to be unknown. Specific treatment was given in 2 (16.66%) while 9 (75.00%) cases 
required symptomatic treatment.  
 
As per Naranjo scale 6 (6.25%) were probable, 57(59.37%) were possible, 0% 
were definite and 37(38.54%) were unlikely. Of the reported ADRs moderate reactions 
accounted for 8 (66.66%) followed by mild 4 (38.34%) and no reactions were found to be 
severe.  
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DISCUSSION 
 
Antibiotics are used for treatment and prophylaxis of various infectious conditions 
and are considered as safer drugs when used rationally. But, like other drugs, they also show 
some adverse reactions in various patient conditions. In the studies carried out in  Nigerian 
children and R. Priyadharsini et al. antibiotics are the most accounted drug class in ADR 
occurrence. Infants and very young children are at high risk of developing ADRs than 
adults because their capacity to metabolize drugs is not fully developed. 
 
In this study, predominance of male sex for adverse drug reactions may be due to 
majority of the admitted paediatric patients were male with more antibiotic use during the 
study period. The study conducted by  Jimmy Jose et al. and  Suthar J.V and Desai S.V also 
showed male predominance, where as    two other studies by G .Starveva et al. and M.M 
Hussain et al. showed female predominance. 
 
More number of antibiotic  adverse drug reactions were detected  in general paediatric 
medicine department, and may be due to increased use of antibiotics in these departments for 
treatment and prophylaxis of various diseases. The documented antibiotic adverse drug 
reactions were mainly affecting GIT and skin and this study also pointed out the same. The 
study of Benjamin Horen et al. and PJ Annie also found the predominance of gastrointestinal 
system followed by skin in ADR occurrence. 
 
Analysis of the type of reported ADRs according to Rawlin and Thompson revealed 
type A predominance. This result is in line with the study conducted by K.A Oshikoya et al. 
and G. Starveva et al. but in another study by Suthar J.V and Desai S.V, all the reported 
reactions were type B reactions. Type A reactions are dose related and thus were preventable 
from their known pharmacology and there for all of them were potentially avoidable. 
 
The analysis of the fate of the suspected drugs showed that the drug was withdrawn 
in many of the cases and dose altered in some while no change was made with the suspected 
drug in others, Because of considering the risk benefit ratio in specific patients and in some 
cases, the use of antibiotics was according to the culture and sensitivity reports. The results 
revealed that pencillins were the most accounted antibiotic class that cause ADRs in 
paediatrics. This result is in line with the study of R.Priyadharsini et al. ie, vancomycin 
and penicillins were most frequent in their study. 
CONCLUSION  
 
Ultra college of pharmacy, Madurai  Page 67 
 
 
CONCLUSION 
 
Adverse drug reactions are one of the drug related problems in the hospital setting 
and is a challenge for the ensuring drug safety. Antibiotics comprise the major volume of the 
drug family and inpatient prescriptions, and are the most irrationally prescribed drug class.  
So that implementation of antibiotic guidelines form the hospital scenario and strict 
adherence should be ensured to promote their rational use in children. The health system 
should promote the spontaneous reporting of adverse drug  reactions,  proper  documentation  
and    periodic reporting to regional pharmacovigilance centers to ensure drug safety. 
 
The most commonly prescribed drugs are those most often implicated in ADRs in 
children. Penicillins, cephalosporins, aminoglycosides etc. are the commonly prescribed 
class of anti-infective agents in paediatric department, during the study  period. The 
antibiotic class mostly affected with ADRs was found to be penicillins followed by 
cephalosporins. 
 
The study concluded that spontaneous reporting of Adverse Drug Reaction is farely 
good in our hospital setting. ADRs may increase costs of patient care and may mimic 
disease, resulting in unnecessary investigations and delay in treatment. Active involvement of 
a well trained clinical pharmacist for detecting the Adverse Drug Reaction and delivering the 
awareness classes for the healthcare professionals regarding the need of reporting ADRs, 
particularly those that are serious or rare. 
 
  
 
 
 
 
 
 
 
ANNEXURE 
  
 
ANNEXURE NO: 1 NARANJO SCALE 
 
 
Patient Name:              Sex:        Age:         I.P No:              Dept:                      Consultant: 
 
 
 
S.NO QUESTIONS YES NO N.K SCORE 
1 Are there previous conclusive reports on this 
reaction? 
    
2. Did the adverse event appear after the suspected drug 
was administered? 
    
3 Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was 
administered? 
   
4 Did the adverse drug reaction reappear when the drug 
was read ministered? 
    
5 Are there alternative causes (other than the drug) that 
could solely have caused the reaction? 
    
6 Did the reaction reappear when a placebo was given?     
7 Was the drug detected in the blood (or other fluids) in 
concentration known to be toxic? 
    
8 Was the reaction more severe when the dose was 
increased or less severe when the dose was decreased? 
    
9 Did the patient have a similar reaction to the same 
drug or similar drugs in any previous exposure? 
    
10 Was the adverse event confirmed by any objective 
evidence? 
    
 
  
  
ANNEXURE NO:6 ADVERSE DRUG REACTION REPORTING & 
DOCUMENTATION FORM  
 
 
  
C.G.M HEALTH CARE S.S.V HOSPITAL PUNALUR 
  
ANNEXURE NO: 5 ALERT CARD  
C.G.M HEALTH CARE S.S.V 
HOSPITAL PUNALUR 
  
ANNEXURE NO : 7  
SCALES FOR DETERMININING SEVERITY, PREDICTABILITY & 
PREVENTABILITY OF ADR 
 
 
 ADR SEVERITY ASSESSMENT SCALE 
 
 
(Modified Hart wig and Siegel) 
   Mild: 
 
Level 1: The ADR requires no change in treatment with suspected 
drug. Or 
Level 2: The ADR requires that the suspected drug be withheld, discontinued, or 
otherwise changed. No antidote or other treatment is required, and there is no increase in 
length of stay. 
 
• Moderate: 
Level 3: The ADR requires that the suspected drug be withheld, discontinued otherwise 
changed, and or an antidote or other treatment is required. There is no increase in length of 
stay. 
Or 
Level 4(a): Any level 3 ADR that increases length of stay by at least one 
day. Or 
Level 4(b): The ADR is the reason for 
Admission. 
 
• Severe: 
Level 5: Any level 4 ADR that requires intensive medical care. 
Or 
Level 6: The ADR causes permanent harm to the patient. 
Or 
Level 7: The ADR either directly or indirectly leads to death of the patient. 
  
  
PATIENT CONSENT FORM 
 
I………………………exercising my power of choice hereby give my 
consent to be included in the study on “A prospective Study of adverse 
drug reaction of anti infective agents in paediatric patients” 
conducted by Bino Babu, Post graduate student in C.G.M Health care 
sree shanmugha vilasam Hospital , Punalur, Kollam 
 
The principal investigator had informed me about the complete 
description of the study 
I whole heartedly without any compulsion agree to give all the relevant 
data regarding the study. 
I am aware of to opt out this study at any given time without hindrance. 
I will not be subjected to any harmful tests as a part of this study 
I need not suffer any economic liabilities for this study. 
 
Date 
 Name of the Patient/Caregiver 
 
Address of Investigator 
 
Bino Babu 
2nd Year M.Pharm Student 
Ultra College of Pharmacy, Madurai 
  
ANNEXURE NO: 3 ADVERSE DRUG REACTION REPORTING & 
DOCUMENTATION FORM  
 
 
 
C.G.M HEALTH CARE S.S.V HOSPITAL PUNALUR 
  
 
 
 
 
ANNEXURE NO: 2 ADVERSE DRUG REACTION REPORTING CARD  
 
 
 
 
 
 
 
 
C.G.M HEALTH CARE S.S.V HOSPITAL PUNALUR 
  
ANNEXURE NO: 4 THANK YOU FORM  
 
 
 
 
 
 
 
C.G.M HEALTH CARE S.S.V HOSPITAL 
PUNALUR 
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